QS Investors’s Achillion Pharmaceuticals ACHN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-432,748
| Closed | -$2.63M | – | 1732 |
|
|
2019
Q4 | $2.63M | Sell |
432,748
-6,548
| -1% | -$37.9K | 0.03% | 495 |
|
|
2019
Q3 | $1.58M | Buy |
439,296
+600
| +0.1% | +$2.31K | 0.02% | 642 |
|
|
2019
Q2 | $1.18M | Sell |
438,696
-10,607
| -2% | -$31.3K | 0.01% | 753 |
|
|
2019
Q1 | $1.33M | Hold |
449,303
| – | – | 0.01% | 736 |
|
|
2018
Q4 | $715K | Hold |
449,303
| – | – | 0.01% | 842 |
|
|
2018
Q3 | $1.65M | Hold |
449,303
| – | – | 0.02% | 671 |
|
|
2018
Q2 | $1.27M | Buy |
449,303
+53
| +0% | +$181 | 0.01% | 725 |
|
|
2018
Q1 | $1.67M | Sell |
449,250
-30,113
| -6% | -$98.5K | 0.02% | 631 |
|
|
2017
Q4 | $1.38M | Sell |
479,363
-18,972
| -4% | -$68.9K | 0.01% | 719 |
|
|
2017
Q3 | $2.24M | Buy |
498,335
+119,765
| +32% | +$532K | 0.02% | 578 |
|
|
2017
Q2 | $1.74M | Buy |
378,570
+101,018
| +36% | +$406K | 0.01% | 629 |
|
|
2017
Q1 | $1.17M | Hold |
277,552
| – | – | 0.01% | 762 |
|
|
2016
Q4 | $1.15M | Hold |
277,552
| – | – | 0.01% | 730 |
|
|
2016
Q3 | $2.25M | Hold |
277,552
| – | – | 0.02% | 620 |
|
|
2016
Q2 | $2.17M | Hold |
277,552
| – | – | 0.02% | 620 |
|
|
2016
Q1 | $2.14M | Buy |
277,552
+277,522
| +925,073% | +$2.03M | 0.02% | 627 |
|
|
2015
Q4 | $1K | Buy |
+30
| New | +$273 | ﹤0.01% | 1953 |
|
|
2015
Q3 | – | Sell |
-6,778
| Closed | -$60K | – | 1486 |
|
|
2015
Q2 | $60K | Sell |
6,778
-158,117
| -96% | -$1.5M | ﹤0.01% | 1225 |
|
|
2015
Q1 | $1.63M | Hold |
164,895
| – | – | 0.02% | 638 |
|
|
2014
Q4 | $2.02M | Buy |
+164,895
| New | +$2.01M | 0.02% | 585 |
|
QS Investors's ACHN Position: Q1 2020 in Review
QS Investors sold out of Achillion Pharmaceuticals (ACHN) in Q1 2020, closing a stake of 432,748 shares — an estimated $2.63M sold.
QS Investors first reported a position in ACHN in Q4 2014 and held it in 20 quarters. The position peaked at $2.63M in Q4 2019. 0 funds tracked by Wall St. Rank hold ACHN as of Q1 2020.
- QS Investors reported no remaining Achillion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
- QS Investors sold 432,748 Achillion Pharmaceuticals shares in Q1 2020, an estimated $2.63M.
- QS Investors first reported a position in Achillion Pharmaceuticals in Q4 2014 and held it in 20 quarters.
- QS Investors's Achillion Pharmaceuticals position peaked at $2.63M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2020.
Based on QS Investors's 13F filing for Q1 2020, filed 15 May 2020.